{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovary+Disease&page=14",
    "query": {
      "condition": "Ovary Disease",
      "page": 14
    },
    "page_size": 10
  },
  "pagination": {
    "page": 14,
    "page_size": 10,
    "total_count": 2268,
    "total_pages": 227,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovary+Disease&page=15&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovary+Disease&page=13&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T06:26:48.690Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06619236",
      "title": "Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Platinum-resistant Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "Rina-S",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Topotecan",
          "type": "DRUG"
        },
        {
          "name": "Pegylated liposomal doxorubicin (PLD)",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genmab",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 584,
      "start_date": "2025-02-07",
      "completion_date": "2027-10",
      "has_results": false,
      "last_update_posted_date": "2026-09-28",
      "last_synced_at": "2026-10-23T06:26:48.690Z",
      "location_count": 72,
      "location_summary": "Anchorage, Alaska • Scottsdale, Arizona • Tucson, Arizona + 60 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06619236"
    },
    {
      "nct_id": "NCT00692900",
      "title": "Safety Study Involving Oxaliplatin With Docetaxel for Recurrent Ovarian,Primary Peritoneal, and Fallopian Tube Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Peritoneal Cancer",
        "Fallopian Tube Cancer"
      ],
      "interventions": [
        {
          "name": "intravenous docetaxel with intraperitoneal oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "intravenous oxaliplatin with intraperitoneal docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 25,
      "start_date": "2008-12",
      "completion_date": "2013-10",
      "has_results": false,
      "last_update_posted_date": "2020-03-12",
      "last_synced_at": "2026-10-23T06:26:48.690Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00692900"
    },
    {
      "nct_id": "NCT02708511",
      "title": "Copper Cu 64-DOTA-B-Fab PET/CT in Imaging Patients With Ovarian and Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ovarian Carcinoma",
        "Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Computed Tomography",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Copper Cu 64-DOTA B-Fab",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Sanjiv Sam Gambhir",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 2,
      "start_date": "2016-08",
      "completion_date": "2017-10-11",
      "has_results": false,
      "last_update_posted_date": "2018-04-05",
      "last_synced_at": "2026-10-23T06:26:48.690Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02708511"
    },
    {
      "nct_id": "NCT00520013",
      "title": "Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Primary Peritoneal Cancer",
        "Papillary Serous Mullerian Tumor",
        "Clear Cell Mullerian Tumor"
      ],
      "interventions": [
        {
          "name": "bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "erlotinib",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 60,
      "start_date": "2007-08",
      "completion_date": "2013-11",
      "has_results": true,
      "last_update_posted_date": "2018-07-27",
      "last_synced_at": "2026-10-23T06:26:48.690Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00520013"
    },
    {
      "nct_id": "NCT07306559",
      "title": "A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Relapsed or Refractory Germ Cell Tumours",
        "Advanced Relapsed or Refractory Endometrial Cancer",
        "Advanced Relapsed or Refractory Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "BI 3820768",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 187,
      "start_date": "2026-02-27",
      "completion_date": "2030-01-28",
      "has_results": false,
      "last_update_posted_date": "2026-08-21",
      "last_synced_at": "2026-10-23T06:26:48.690Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Indianapolis, Indiana • Houston, Texas",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07306559"
    },
    {
      "nct_id": "NCT03784859",
      "title": "Tissue Expansion in Breast Reconstruction Without Drains",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Cancer",
        "Hereditary Breast and Ovarian Cancer Syndrome",
        "Breast Implant; Complications"
      ],
      "interventions": [
        {
          "name": "Insertion of Tissue Expander with Fluid Reservoir",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Cedars-Sinai Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "21 Years and older · Female only"
      },
      "enrollment_count": 5,
      "start_date": "2019-02-25",
      "completion_date": "2020-10-02",
      "has_results": false,
      "last_update_posted_date": "2020-10-06",
      "last_synced_at": "2026-10-23T06:26:48.690Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03784859"
    },
    {
      "nct_id": "NCT02718417",
      "title": "Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Avelumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 998,
      "start_date": "2016-05-19",
      "completion_date": "2019-05-16",
      "has_results": true,
      "last_update_posted_date": "2020-07-14",
      "last_synced_at": "2026-10-23T06:26:48.690Z",
      "location_count": 146,
      "location_summary": "Alabaster, Alabama • Bessemer, Alabama • Birmingham, Alabama + 70 more",
      "locations": [
        {
          "city": "Alabaster",
          "state": "Alabama"
        },
        {
          "city": "Bessemer",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02718417"
    },
    {
      "nct_id": "NCT06962059",
      "title": "Healthy Volunteers Study",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Ovarian Cancer",
        "Genetic Predisposition to Disease"
      ],
      "interventions": [
        {
          "name": "Self-Administered Sample Collection",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Abramson Cancer Center at Penn Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "30 Years to 50 Years · Female only"
      },
      "enrollment_count": 50,
      "start_date": "2025-04-21",
      "completion_date": "2027-05-25",
      "has_results": false,
      "last_update_posted_date": "2026-02-05",
      "last_synced_at": "2026-10-23T06:26:48.690Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06962059"
    },
    {
      "nct_id": "NCT03634982",
      "title": "Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "RMC-4630",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Revolution Medicines, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 133,
      "start_date": "2018-09-28",
      "completion_date": "2023-05-31",
      "has_results": false,
      "last_update_posted_date": "2022-09-01",
      "last_synced_at": "2026-10-23T06:26:48.690Z",
      "location_count": 12,
      "location_summary": "Scottsdale, Arizona • Duarte, California • Orange, California + 9 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03634982"
    },
    {
      "nct_id": "NCT05523440",
      "title": "Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Endometrial Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "ARID1A Gene Mutation"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Niraparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Oklahoma",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 9,
      "start_date": "2023-02-15",
      "completion_date": "2025-01-08",
      "has_results": true,
      "last_update_posted_date": "2026-06-03",
      "last_synced_at": "2026-10-23T06:26:48.690Z",
      "location_count": 2,
      "location_summary": "Oklahoma City, Oklahoma • Charlottesville, Virginia",
      "locations": [
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05523440"
    }
  ]
}